GO:0008543 fibroblast growth factor receptor signaling pathway: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008543 describes the molecular signaling cascade triggered when a fibroblast growth factor (FGF) ligand binds to a fibroblast growth factor receptor (FGFR).
• FGFR signaling is essential for embryonic development, tissue homeostasis, and regeneration, and its dysregulation drives cancers, skeletal disorders, and metabolic diseases [1,2,5,7].
• The pathway involves ligand-induced receptor dimerization, autophosphorylation, and activation of downstream cascades including RAS-MAPK, PI3K-AKT, and PLCγ [1,5].
• Key genes include FGFR1-4, FGF ligands, and downstream effectors such as FRS2, GRB2, and SOS1 [1,5].
• Aberrant FGFR signaling is implicated in skin cancers, breast cancer, soft tissue sarcomas, and metabolic dysfunction-associated fatty liver disease [1,2,3,8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are powerful tools to dissect FGFR pathway function and validate therapeutic targets [4,6].
Description
The fibroblast growth factor receptor signaling pathway (GO:0008543) is a fundamental biological process that governs how cells respond to fibroblast growth factor (FGF) ligands. This pathway is initiated when an FGF ligand binds to its cognate FGFR on the cell surface, leading to receptor dimerization and activation of intracellular signaling cascades. It plays critical roles in embryonic development, tissue repair, and metabolic regulation, and its dysfunction is associated with a wide range of human diseases, including cancers and skeletal disorders [1,2,5,7]. Researchers study this pathway to understand normal physiology and to develop targeted therapies for diseases driven by aberrant FGFR signaling [3,8].
fibroblast growth factor receptor signaling pathway At A Glance
| GO ID | GO:0008543 |
|---|---|
| GO term | fibroblast growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | FGF receptor signaling pathway, FGF receptor signalling pathway, FGFR signaling pathway, fibroblast growth factor receptor signalling pathway |
| Major function | Transduces signals from FGF ligands to regulate cell proliferation, differentiation, migration, and survival [1,5]. |
| Key receptors | FGFR1, FGFR2, FGFR3, FGFR4 [1,3]. |
| Key ligands | FGF1, FGF2, FGF4, FGF8, FGF19, etc. [1,2]. |
| Downstream pathways | RAS-MAPK, PI3K-AKT, PLCγ, STAT [1,5]. |
| Disease relevance | Cancer, skeletal dysplasias, metabolic disorders [1,2,3,7]. |
What Is GO:0008543?
According to the Gene Ontology, GO:0008543 is defined as the series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands. In other words, it encompasses all the molecular events that occur after an FGF ligand activates an FGFR, including receptor autophosphorylation, recruitment of adaptor proteins, and activation of downstream signaling cascades that ultimately lead to changes in gene expression, cell proliferation, differentiation, and survival [1,5].
Why Is fibroblast growth factor receptor signaling pathway Important in Cell Biology?
The fibroblast growth factor receptor signaling pathway is critically important because it controls fundamental cellular processes such as proliferation, differentiation, migration, and survival, and it is essential for embryonic development and tissue homeostasis [1,5]. Dysregulation of this pathway is a hallmark of many cancers, including skin cancers, breast cancer, and soft tissue sarcomas, where aberrant FGFR activation promotes tumor growth and progression [1,3,8]. Moreover, mutations in FGFR genes cause skeletal disorders and contribute to metabolic diseases such as metabolic dysfunction-associated fatty liver disease [2,7]. Understanding this pathway is therefore vital for developing targeted therapies and for advancing regenerative medicine [4,6].
• Regulates embryonic development, including limb formation and skeletal patterning [5,7].
• Controls tissue homeostasis and wound healing in adult organisms.
• Drives oncogenesis in multiple cancers, such as melanoma, breast cancer, and sarcomas [1,3,8].
• Mutations in FGFR genes cause craniosynostosis and skeletal dysplasias.
• Implicated in metabolic dysfunction-associated fatty liver disease (MAFLD).
• Modulates cholesterol storage and tumor cell invasion in breast cancer.
• Required for dendrite regeneration in neurons.
• Serves as a target for small-molecule inhibitors and antibody-based therapies [3,8].
• Provides a paradigm for understanding receptor tyrosine kinase signaling.
• Offers opportunities for CRISPR-based functional genomics and drug discovery [4,6].
What Happens During fibroblast growth factor receptor signaling pathway?
Ligand Binding and Receptor Dimerization
In simple terms: An FGF ligand binds to an FGFR on the cell surface, causing two receptors to pair up.
The pathway begins when a fibroblast growth factor (FGF) ligand binds to the extracellular domain of a fibroblast growth factor receptor (FGFR). This binding induces receptor dimerization, bringing two FGFR molecules together. Dimerization is stabilized by heparan sulfate proteoglycans, which act as co-receptors. The formation of the ligand-receptor complex is the first committed step in signal transduction and is essential for subsequent activation [1,5].
Receptor Autophosphorylation and Activation
In simple terms: The paired receptors add phosphate groups to each other, switching them on.
Upon dimerization, the intracellular kinase domains of the FGFRs trans-autophosphorylate specific tyrosine residues in the activation loop and juxtamembrane region. This autophosphorylation relieves autoinhibition and creates docking sites for downstream adaptor proteins. Phosphorylation of tyrosine residues such as Y653 and Y654 in FGFR1 is critical for full kinase activation. This step is tightly regulated and is a common target for oncogenic mutations [1,3].
Recruitment of Adaptor Proteins and Activation of RAS-MAPK Cascade
In simple terms: Docking proteins attach to the activated receptor and switch on a chain of kinases that tell the cell to grow.
Phosphorylated FGFRs recruit the adaptor protein FRS2 (FGFR substrate 2), which is constitutively associated with the receptor. FRS2 is then phosphorylated and binds the adaptor GRB2, which in turn recruits the guanine nucleotide exchange factor SOS1. SOS1 activates RAS by exchanging GDP for GTP, leading to activation of RAF, MEK, and ERK. This RAS-MAPK cascade transmits signals to the nucleus to promote cell proliferation and differentiation [1,5].
Activation of PI3K-AKT and PLCγ Pathways
In simple terms: Other branches of the pathway promote cell survival and calcium signaling.
In addition to the RAS-MAPK cascade, FGFR signaling activates the PI3K-AKT pathway. Phosphorylated FGFR or FRS2 recruits the p85 subunit of PI3K, leading to production of PIP3 and activation of AKT, which promotes cell survival and growth. Furthermore, FGFR phosphorylates PLCγ, which hydrolyzes PIP2 to generate IP3 and DAG, triggering calcium release and PKC activation. These branches contribute to diverse cellular responses, including migration and gene expression [1,5].
Negative Feedback and Signal Attenuation
In simple terms: The cell has brakes to shut down the signal after it has done its job.
To prevent excessive signaling, the pathway is attenuated by negative feedback mechanisms. This includes phosphorylation of FRS2 by ERK, which reduces its ability to bind GRB2, and recruitment of phosphatases such as SHP2 that dephosphorylate FGFR. Additionally, ligand-induced receptor internalization and degradation limit signal duration. Dysregulation of these feedback loops can lead to sustained signaling and oncogenesis [1,3].
Key Genes Involved in GO:0008543 fibroblast growth factor receptor signaling pathway
The fibroblast growth factor receptor signaling pathway involves a suite of genes encoding ligands, receptors, adaptors, and downstream effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGFR1 | Receptor tyrosine kinase; binds FGF ligands and initiates signaling | Implicated in breast cancer, skeletal disorders, and stem cell regulation [1,8]. |
| FGFR2 | Receptor tyrosine kinase; mediates signaling in development and cancer | Mutations cause craniosynostosis and cancers [1,7]. |
| FGFR3 | Receptor tyrosine kinase; regulates bone growth and differentiation | Mutations cause achondroplasia and bladder cancer [1,7]. |
| FGFR4 | Receptor tyrosine kinase; involved in liver metabolism and cancer | Target in hepatocellular carcinoma and MAFLD. |
| FGF1 | Ligand for all FGFRs; promotes proliferation and angiogenesis | Studied in wound healing and cancer. |
| FGF2 | Ligand; regulates cell growth and differentiation | Key in stem cell culture and tumor progression. |
| FGF8 | Ligand; critical for embryonic development | Role in limb and brain development. |
| FGF19 | Ligand; regulates bile acid and glucose metabolism | Linked to metabolic diseases and liver cancer. |
| FRS2 | Adaptor protein; links FGFR to RAS-MAPK and PI3K | Essential for FGFR signaling; knockout impairs development. |
| GRB2 | Adaptor protein; recruits SOS1 to activate RAS | Central node in RTK signaling. |
| SOS1 | Guanine nucleotide exchange factor; activates RAS | Mutations affect RASopathies. |
| RAS | Small GTPase; activates RAF-MEK-ERK cascade | Oncogene frequently mutated in cancers. |
| MAPK1 (ERK2) | Kinase; transmits signals to nucleus | Regulates proliferation and differentiation. |
| PIK3CA | Catalytic subunit of PI3K; activates AKT | Oncogene in many cancers. |
| AKT1 | Kinase; promotes survival and growth | Key effector of PI3K pathway. |
| PLCγ1 | Phospholipase; generates IP3 and DAG | Mediates calcium signaling. |
| SOAT1 | Enzyme; cholesterol esterification | Modulated by FGFR signaling in breast cancer. |
| SHP2 (PTPN11) | Phosphatase; attenuates FGFR signaling | Mutations cause Noonan syndrome and cancers. |
How Is fibroblast growth factor receptor signaling pathway Regulated?
The fibroblast growth factor receptor signaling pathway is tightly regulated at multiple levels. Ligand availability is controlled by expression and extracellular matrix binding. Receptor activity is modulated by phosphorylation and dephosphorylation events, with phosphatases such as SHP2 providing negative feedback. Additionally, endocytosis and degradation of the receptor-ligand complex attenuate signaling. Crosstalk with other pathways, such as Wnt and BMP, further fine-tunes the output during skeletogenesis. In disease, dysregulation often occurs through mutations that stabilize the active conformation or through autocrine loops [1,3].
fibroblast growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGFR1 | Breast cancer, craniosynostosis | Knockout or point-mutation in breast cancer cell lines. |
| FGFR2 | Craniosynostosis, endometrial cancer | Knock-in of patient mutations in HEK293 or osteoblast models. |
| FGFR3 | Achondroplasia, bladder cancer | Overexpression of mutant FGFR3 in chondrocytes. |
| FGFR4 | MAFLD, hepatocellular carcinoma | Liver-specific knockout in mice or HepG2 cells. |
| SOAT1 | Breast cancer invasion | Knockout in MDA-MB-231 cells to assess cholesterol storage. |
FGFR Signaling in Cancer
Aberrant activation of FGFR signaling is a driving force in many cancers. In skin cancers, including melanoma and squamous cell carcinoma, FGFR signaling promotes proliferation, survival, and migration. In breast cancer, FGFR1 amplification and overexpression are associated with poor prognosis, and targeting FGFR signaling is a rational therapeutic strategy. Soft tissue sarcomas, such as gastrointestinal stromal tumors (GIST), can also harbor FGFR alterations that contribute to tumorigenesis. Additionally, FGFR signaling modulates cholesterol storage via SOAT1 to enhance mammary tumor cell invasion.
FGFR Signaling in Skeletal Disorders
Mutations in FGFR1, FGFR2, and FGFR3 cause a spectrum of skeletal dysplasias, including craniosynostosis syndromes and achondroplasia. These mutations often lead to ligand-independent receptor activation or altered downstream signaling, affecting bone growth and development. The crosstalk between FGFR and other signaling pathways, such as BMP and Wnt, is critical for proper skeletogenesis, and its disruption contributes to disease pathogenesis.
FGFR Signaling in Metabolic and Regenerative Disorders
Recent studies have implicated FGFR signaling in metabolic dysfunction-associated fatty liver disease (MAFLD), where it regulates lipid metabolism and inflammation. Furthermore, FGFR signaling is required for dendrite regeneration in neurons, highlighting its role in regenerative processes. These findings suggest that modulating FGFR activity could have therapeutic potential beyond oncology.
From fibroblast growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FGFR1 drive tumor growth? | FGFR1 knockout in cancer cell lines (e.g., breast cancer). |
| What is the effect of a specific FGFR2 mutation? | Point mutation knock-in in HEK293 or primary cells. |
| How does FGFR3 fusion affect signaling? | Knock-in of fusion gene in chondrocytes or fibroblasts. |
| Can FGFR4 be targeted in MAFLD? | Liver-specific knockout or overexpression in mice. |
| What is the role of FGFR signaling in dendrite regeneration? | Knockout or knockdown in neuronal cultures. |
| Does FGFR signaling regulate cholesterol storage? | SOAT1 knockout or overexpression in breast cancer cells. |
How to Study the fibroblast growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Identify essential genes in FGFR pathway. |
| CRISPR point mutation | Effect of specific mutations | Model patient-derived FGFR mutations. |
| CRISPR knock-in | Tagged or mutant protein expression | Study receptor trafficking and signaling. |
| RNA-seq | Transcriptional changes | Identify downstream targets of FGFR signaling. |
| Phosphoproteomics | Phosphorylation events | Map signaling networks. |
| Cell proliferation assay | Cell growth | Assess oncogenic potential. |
| Live-cell imaging | Receptor dynamics | Visualize internalization and localization. |
| Xenograft models | Tumor growth in vivo | Test FGFR inhibitors. |
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 is widely used to create knockout, point mutation, and knock-in models to study FGFR signaling. For example, knockout of FGFR1 in breast cancer cells can reveal its role in proliferation and survival. Point mutations can be introduced to mimic patient-specific alterations, such as FGFR2 mutations in craniosynostosis. Knock-in of tagged receptors allows visualization and biochemical analysis of signaling dynamics.
Transcriptomic and Proteomic Profiling
RNA sequencing (RNA-seq) and mass spectrometry-based proteomics are used to identify global changes in gene expression and protein phosphorylation upon FGFR activation or inhibition. These approaches can uncover downstream effectors and feedback mechanisms [1,5]. For instance, phosphoproteomics can map the signaling network downstream of FGFR1.
Functional Assays and Imaging
Cell-based assays such as proliferation, migration, and invasion assays are used to assess the functional consequences of FGFR signaling. Live-cell imaging with fluorescently tagged FGFRs can visualize receptor internalization and trafficking. In vivo models, including zebrafish and mice, provide insights into developmental and regenerative roles.
Pharmacological Inhibition and Resistance Studies
Small-molecule FGFR inhibitors (e.g., erdafitinib, pemigatinib) are used to block signaling and assess therapeutic efficacy. Resistance mechanisms can be studied by generating resistant cell lines through chronic exposure and CRISPR screens [3,8].
How CRISPR Can Be Used to Study GO:0008543 fibroblast growth factor receptor signaling pathway
Knockout
CRISPR knockout of FGFR genes or downstream effectors is used to abrogate signaling and study loss-of-function phenotypes. For example, FGFR1 knockout in breast cancer cells reduces proliferation and tumor growth. Knockout of FRS2 or GRB2 disrupts the entire pathway, confirming their essential roles.
Point Mutation
Point mutations can be introduced to model specific FGFR alterations found in patients, such as FGFR2 S252W in craniosynostosis or FGFR3 G380R in achondroplasia. These models help understand how mutations affect receptor activity and downstream signaling.
Knock-in
Knock-in of tagged FGFRs (e.g., GFP or HA) allows real-time tracking of receptor localization and interaction. Knock-in of fusion genes, such as FGFR3-TACC3, models oncogenic fusions found in glioblastoma and other cancers.
Overexpression
Overexpression of wild-type or mutant FGFRs is used to study gain-of-function effects, such as ligand-independent activation and oncogenic transformation. Overexpression of FGF ligands can also mimic autocrine signaling loops in tumors [1,3].
How EDITGENE Supports fibroblast growth factor receptor signaling pathway Research
Researchers studying fibroblast growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for fibroblast growth factor receptor signaling pathway research.
Frequently Asked Questions About fibroblast growth factor receptor signaling pathway
What is the fibroblast growth factor receptor signaling pathway?
It is the series of molecular signals triggered when an FGF ligand binds to an FGFR, leading to receptor activation and downstream cellular responses.
What genes are involved in FGFR signaling?
Key genes include FGFR1-4, FGF ligands (e.g., FGF1, FGF2), adaptors (FRS2, GRB2), and effectors (RAS, MAPK, PI3K, AKT) [1,5].
What diseases are associated with FGFR signaling?
Cancers (skin, breast, sarcomas), skeletal dysplasias, and metabolic disorders such as MAFLD [1,2,3,7].
How is FGFR signaling regulated?
It is regulated by ligand availability, receptor phosphorylation/dephosphorylation, endocytosis, and negative feedback loops.
What are the downstream pathways of FGFR?
Major downstream pathways include RAS-MAPK, PI3K-AKT, and PLCγ [1,5].
How can I study FGFR signaling using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of the pathway [4,6].
What is the role of FGFR signaling in cancer?
It promotes proliferation, survival, migration, and angiogenesis, and its dysregulation drives tumorigenesis [1,3,8].
Which FGFR is most commonly mutated in skeletal disorders?
FGFR3 mutations are common in achondroplasia, while FGFR2 mutations cause craniosynostosis.
What is the link between FGFR signaling and metabolism?
FGFR4 and FGF19 regulate bile acid and lipid metabolism, and their dysregulation contributes to MAFLD.
What CRISPR services does EDITGENE offer for FGFR research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics analysis [4,6].
Conclusion
The fibroblast growth factor receptor signaling pathway (GO:0008543) is a central regulator of development, tissue homeostasis, and disease. Its dysregulation is implicated in a broad spectrum of cancers, skeletal disorders, and metabolic diseases, making it a prime target for therapeutic intervention [1,2,3,7]. Advances in CRISPR-based genome editing have revolutionized the study of this pathway, enabling precise functional interrogation of genes and mutations [4,6]. EDITGENE's comprehensive services empower researchers to create tailored cell models and accelerate discoveries in FGFR biology.
References
- 1. Czyz M. 2019. Fibroblast Growth Factor Receptor Signaling in Skin Cancers.. Cells 8(6) PMID: 31167513
- 2. Chu Y et al.. 2025. Fibroblast growth factor receptor signaling in metabolic dysfunction-associated fatty liver disease: Pathogenesis and therapeutic targets.. Pharmacol Ther 269:108844 PMID: 40113178
- 3. Napolitano A et al.. 2021. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.. Cells 10(6) PMID: 34204560
- 4. Tuokkola JE et al.. 2025. Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion.. Breast Cancer Res 27(1):132 PMID: 40665359
- 5. Miraoui H et al.. 2010. Fibroblast growth factor receptor signaling crosstalk in skeletogenesis.. Sci Signal 3(146):re9 PMID: 21045207
- 6. Singh P et al.. 2026. The conserved fibroblast growth factor receptor-based signaling is required for dendrite regeneration.. Proc Natl Acad Sci U S A 123(12):e2506886123 PMID: 41849383
- 7. Tuzon CT et al.. 2019. Nuclear Fibroblast Growth Factor Receptor Signaling in Skeletal Development and Disease.. Curr Osteoporos Rep 17(3):138-146 PMID: 30982184
- 8. André F et al.. 2015. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.. Breast Cancer Res Treat 150(1):1-8 PMID: 25677745
